Clinical Trial Search

Primary: Number of Participants With Progression-free Survival at 6 Months — 3 Participants

Primary: Objective Response Rate — 56.4 percentage of participants

Primary: Best Tumor Response (Complete [CR] or Partial Response [PR] by Response Evaluation Criteria in Solid Tumors [RECIST]) — 0; 0 participants

Primary: The Number of Participants Experiencing an Unacceptable Level of Toxicity as Defined Below — 9; 6; 2; 4 Participants

Primary: Median Overall Survival — 13.9 months

Primary: Progression-Free Survival (PFS) — 2.8; 5.4; 1.6 months

Primary: Bladder Tumor Recurrence Rate — 41.37 percentage of subjects

Primary: Objective Response Rate (ORR, CR+PR) in Patients With Advanced/Metastatic UC Treated With the Combination of Gemcitabine, Cisplatin, and Sunitinib. — 48.5 Percentage of…

Primary: Overall Objective Response — 3; 29; 39 participants

Primary: Percentage of Participants Free From Radical Cystectomy at 3 Years — 88.2 percentage of participants

Primary: Median Yield of Robot Assisted and Second Look Open Pelvic Lymph Node Dissection to Compare the Lymph Node Yield Achieved — 43; 4 Nodes (Node Yield)

Primary: Objective Tumor Response — 15 Participants

Primary: Progression Free Survival — 8.2 months

Primary: The Pathologic Complete Response Rate (<pT0) of Neoadjuvant GCS Regimen in Patients With Muscle-invasive Bladder Cancer. — 6.67 percentage of participants

Primary: Phase Ib: Safety of Pembrolizumab in Combination With Gemcitabine-Cisplatin — 0 Participants

Primary: Disease Recurrence Rate — 27.86; 40 percentage of patients with recurrence — p=0.01

Primary: Number of Participants With Presence of Fluorescence of cT1 RCC in Partial Nephrectomy Specimens — 10 Participants

Primary: Number of Participants With Any Serious Adverse Events (SAEs) — 1 Participants

Primary: Number of Participants With 18F-DCFPyL PET/CT Detected Sites of Metastatic Renal Cell Carcinoma (RCC) — 34 Participants

Primary: Number of Participants With Adverse Events — 2 Participants

Primary: Response Rate — 8 Participants

Primary: Progression Free Survival (PFS) of Carfilzomib Therapy in Participants With Refractory Or Intolerant to Prior Therapy — 1.8 Months

Primary: Response Rate by Solid Tumor Response Criteria (RECIST) — 16 Percentage of Participants

Primary: Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin — 56; 253; 3093; 29773 participants — p=<0.0001

Primary: Objective Response Rate (ORR) — 69.6; 33.3 Percentage of participants

Primary: Toxicity for Safety Monitoring (TOX) — 15 percentage of participants

Primary: Number of Participants With Complete Response at 3 Months — 26 Participants

Primary: Urinary Tract Infection After Percutaneous Nephrostomy Procedure — 5; 10 Percutaneous nephrostomy procedure — p=0.548

Primary: Progression Free Survival — 1.9 Months

Primary: Safety and Tolerability — 5; 2; 1; 1 Grade 1/2 event count (no grade 3+)